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Abstract
Background: Ukraine has experienced an increase in injection drug use since the 1990s. An
increase in HIV and hepatitis C virus infections has followed, but not measures of prevalence and
risk factors. The purposes of this study are to estimate the prevalence of HIV, HCV, and co-
infection among injection drug users (IDUs) in central Ukraine and to describe risk factors for HIV
and HCV.
Methods: A sample of 315 IDUs was recruited using snowball sampling for a structured risk
interview and HIV/HCV testing (81.9% male, 42% single, average age 28.9 years [range = 18 to 55]).
Results: HIV and HCV antibodies were detected in 14.0% and 73.0%, respectively, and 12.1% were
seropositive for both infections. The most commonly used drug was hanka, home-made from
poppy straw and often mixed with other substances including dimedrol, diazepines, and hypnotics.
The average period of injecting was 8.5 years; 62.5% reported past-year sharing needles or injection
equipment, and 8.0% shared with a known HIV-positive person. More than half (51.1%) reported
multiple sexual partners, 12.9% buying or selling sex, and 10.5% exchanging sex and drugs in the
past year. Those who shared with HIV positive partners were 3.4 times more likely to be HIV
positive than those who did not. Those who front- or back-loaded were 4 times more likely to be
HCV positive than those who did not.
Conclusion: Harm reduction, addiction treatment and HIV prevention programs should address
risk factors to stop further spread of both HIV and HCV among IDUs and to the general population
in central Ukraine.
Background
Ukraine is the second largest country in Eastern Europe,
with an estimated population of about 48 million. Politi-
cal independence in Ukraine and surrounding Eastern
European countries in the early 1990s has been associated
with a rapid increase in the supply, use, and negative pub-
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lic health consequences of illicit drugs [1]. The number of
persons officially registered at psychiatric/narcological
facilities as drug-dependent patients increased from
51,484 in 1996 to 80,145 in 2008 [2]. The increased prev-
alence of narcotics addiction and demand for opiate
drugs, along with the high cost of imported heroin in a
developing country, have prompted expansion of cheaper
intravenous solutions that are home-made from locally
grown poppy. Home-made acetylated opioid solution,
called hanka, is currently the most commonly used intra-
venous addictive drug in Ukraine, as opposed to Russia
and Belarus, where heroin is more easily available[3].
The main source of hanka is locally grown poppy, which
can be harvested for latex during June and July or dried for
later use. Poppy latex can be used in a number of ways. It
can be dissolved and injected; dried and smoked as
opium; dried on a glass, scratched off and then snorted;
and ingested. Poppy seed capsules and stems can be col-
lected, dried and crushed into poppy straw for later use.
Straw can be chewed and ingested or brewed in water to
make poppy tea (kuknar), but the most common process-
ing method is to refine the straw into acetylated morphine
by a simple acid-base extraction. This process, involving
solvents and acetic anhydride, produces a dark solution
known as hanka or shirka that can be injected intrave-
nously or intramuscularly. Users reported switching to
intramuscular injection when peripheral veins obliterated
(burned out) and phlebitis or personal discomfort pre-
vented use of central veins.
The reported number of cases of HIV in Ukraine increased
from 398 at the beginning of 1995 to 141,277 at the
beginning of 2009 [4]. The true number of HIV cases
among adults aged 15–49 by the end of 2007 was esti-
mated to be somewhere between 230,000 and 573,000
[5], which yields an overall prevalence of 1.63%. The few
available local sources show that HIV disproportionately
affects injection drug users (IDUs), and regional preva-
lence ranges from 8.7% to 58.3% [6-8]. Hepatitis C virus
(HCV) is even more common in IDUs, with regional prev-
alence ranging from 62% to 88% [7,9,10]. While HIV may
be transmitted through multiple routes, HCV in IDUs is
transmitted mainly via percutaneous exposure. A recent
study showed that positive HIV status among Ukrainian
IDUs was associated with female sex, daily injections,
combined stimulant/opiate use, and having sex with HIV
positive persons [11]. Thus, the risk factors for HIV and
HCV infections among IDUs may differ and therefore lead
to the different prevalence for the two infections. The pur-
pose of this study was to document: 1) prevalence of HIV,
HCV, and co-infection; 2) the current nature and extent of
non-heroin opiate IDU patterns; and 3) sex- and drug-
related risk factors that may differentiate HIV and HCV
infections in an understudied rural area of central
Ukraine.
Methods
Study setting
Vinnitsya is a mid-size oblast (region) in central Ukraine
with a total population of 380,000, and the majority of
local residents are farmers. At the end of 2008, a total of
1,299 HIV/AIDS cases have been registered in Vinnitsya
Oblast. Most of these infections were attributed to IDU,
although the proportion of IDUs among newly registered
cases has declined from 77% in 1998 to 31.5% in 2008
[12]. The official number of persons in the Vinnitsya
Oblast registered as drug-dependent patients at the
Regional Narcological Dispensary (RND) at the end of
2008 was 1,146 [13]. However, the estimated figure is 5 to
7 times greater due to under-reporting [14]. This cross-sec-
tional survey was conducted in 2005 to investigate the
prevalence of HIV and HCV and associated risk factors
among opiate IDUs in Vinnitsya, Ukraine, in collabora-
tion with local investigators from the Infectious Disease
Hospital, Vinnitsya National Medical University –
Pirogov and the RND. The Fogarty International Center of
the National Institutes of Health funded the study.
Study participants
Study participants were recruited using a snowball sam-
pling technique [15]. Seven initial "seeds" were recruited
through the registered patient population of the RND.
They were screened for the history of active injection drug
use and also were selected to represent different city dis-
tricts in the Vinnitsya Oblast. Upon discharge, they were
offered the opportunity to refer their drug injecting peers
for HIV testing and counseling for a referral fee ($2 US per
referral). There was no limit on the number of referrals by
each seed. This approach worked very well; within several
weeks, the number of eligible IDUs willing to participate
almost exceeded the testing capacity of the study site. The
desired sample size was reached in three months. We esti-
mate that our sample represented 15 to 20% of the IDU
population in the city, based on the official registry of
drug-dependent persons maintained by the RND.
Inclusion criteria for participating in the study included:
1) Age ≥ 18; 2) self-reported history of at least three injec-
tions of illicit drugs in the past 30 days; 3) residence in
Vinnitsya for the past year; and 4) ability and willingness
to give informed consent. The self-reported history of
illicit drug injection was confirmed by probing knowledge
of drug-related issues or the observed presence of physical
needle marks. This criterion was not used to rule out new
or careful users, but rather non-users attempting to earn
the study incentive. No volunteers were excluded for lack
of physical stigmata alone, nor was prior HIV or HCV test-
ing an exclusion criterion. The study was approved by the
institutional review and scientific ethics boards of The
University of Alabama at Birmingham and the Vinnitsya
National Medical University – Pirogov.Harm Reduction Journal 2009, 6:23 http://www.harmreductionjournal.com/content/6/1/23
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Data collection
After the initial eligibility screening, research staff (KD,
RS, OZ) explained the study to each participant; obtained
written informed consent; and provided participants with
HIV pre-test counseling, following the US Centers for Dis-
ease for Control (CDC) guidelines [16] and comple-
mented by a corresponding HCV protocol created by the
investigators. A structured interview was then adminis-
tered by trained interviewers at the Infectious Diseases
Hospital. It included demographic information, HIV
knowledge (HIV-KQ-45), the Form 90 for lifetime and
past 30-day drug use history, and the Risk Assessment Bat-
tery (RAB) for sex- and drug-related HIV risk behaviors in
the past 6 months [17-19]. Participants also were asked if
they ever used needle exchange programs, which were
available in the study locale during the time that this
research was conducted. Qualitative information on cul-
turally specific aspects of drug purchase, use and prepara-
tion also was collected in a structured interview. Research
staff asked participants to describe the nature of injection
practices, types of drugs used, purchasing practices, opiate
preparation practices, and modes of IDU. Finger prick
whole blood samples were collected to test for HIV and
HCV antibodies using ACON rapid HIV and HCV tests
(ACON Laboratories, GBI Biotech Co., Ltd., Beijing,
China) after pre-test counseling. Sensitivity and specificity
are reported to reach 99% per the test manual. All partici-
pants then were provided with post-test counseling for
both HIV and HCV results, per CDC guidelines and study
protocol, before they left the study clinic. Participants
with reactive HIV and/or HCV screening tests were
referred to local facilities for diagnostic confirmation and
other medical services. Participants were compensated for
their time and effort with monetary vouchers worth 30
Grivna (about 6 US dollars).
Data analysis
Statistical analyses were performed using SAS version 9.1
(SAS Institute Inc., Cary, NC, USA). Baseline point preva-
lence was calculated for HIV and HCV seropositivity. Uni-
variate analyses were undertaken first to identify factors
associated with HIV and HCV infections, which included
demographic variables, sex and drug use risk behaviors,
and harm reduction experience. Variables significantly
associated with infection status in univariate models (P <
0.05) were included in multivariate logistic regression
models. Those variables that were not significant in the
multivariable models at the significance level of 0.05 were
eliminated in a stage-wise manner, identifying variables
that were independently associated with HCV and HIV
seropositivity. Observations with missing values in any
variables included in the models were excluded from
analysis. Use of recent behaviors as predictors of prevalent
infections is based on the assumption that the behaviors
did not vary post-infection. That is a limitation to this
analytic approach.
Results
Demographics of participants
Among the 380 persons who self-reported injection of
illicit drugs within the past 30 days, 4 were younger than
age 18. Another 61 were ineligible due to the absence of
physical drug injecting signs in combination with poor
knowledge of the local IDU scene and practices and/or
unconvincing statements about personal drug use. Thus,
315 participants were enrolled in this study. Of these,
81.9% were males; 42.0% were single; average age was
28.9 years (range 18–55); 38.1% had at least some college
(post-secondary) education; 31.7% were unemployed;
and 1.3% were homeless.
Drug abuse characteristics
In this study, more than ninety percent (93.6%) reported
intravenously injecting hanka in the past month, and
1.3% were injecting it intramuscularly; 9.3% ingested opi-
ates (through chewing or brewing poppy straw); 7.6%
smoked opium; and 4.2% snorted dried poppy juice.
Hanka is made either by users themselves or by a dealer,
who may be a user as well. In both cases, the solution
often is drawn up from a common container; 70% of the
participants reported using this practice in the past year.
The solution also may be back- or front-loaded from
another syringe (72% in the past year). Dealers usually
use a large 20 ml syringe with a bent needle to front-load
buyers' smaller syringes, which creates a possibility for
mass contamination if one of the buyers uses an infected
syringe.
Different substances often were added to the hanka solu-
tion before injecting in order to boost or prolong its
desired effects, minimize adverse effects (e.g. nausea and
hyperthermia), and improve chemical properties (e.g.,
making the solution look more clear). Participants
reported that whole blood was used in the past to precip-
itate debris during preparation of these drugs, but adding
other substances to alter the subjective effect has become
more common. Only 14.9% of participants reported
using pure hanka over the past month. The majority
mixed it with dimedrol (antihistamine medication,
77.2%), tranquilizers (benzodiazepines, 15.4%), or hyp-
notics (diazepines and others, 2.5%). Substances used
concurrently with opiates (or shortly thereafter) included
an injectable amphetamine-type stimulant named vint,
prepared from over-the-counter medications including
ephedrine (synonyms jeff, effect, boltushka; 4.2%); tra-
madol (prescription opiate analgesic, 3.8%); alcohol
(1.9%); and marijuana (1.3%). Drugs used apart from
opiates included vint (29.5%), ketamine (2.8%), and
ecstasy (1.3%).
HIV and HCV seroprevalence
HIV infection was detected in 44 participants (14.0%) and
HCV infection in 230 (73.0%) out of the 315 total eligibleHarm Reduction Journal 2009, 6:23 http://www.harmreductionjournal.com/content/6/1/23
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IDUs. Thirty-eight participants (12.1%) were seropositive
for both HIV and HCV; 192 (61.0%) had HCV only; and
6 (1.9%) had HIV only (Table 1).
Risky sex and drug use behaviors
About half of all participants (51.1%) reported having
multiple sexual partners (>1) in the past year, and 10.5%
exchanged sex for drugs or drugs for sex (see Table 2).
Among all participants, 53.2% reported no or inconsist-
ent use of condoms during sex. Almost half of the sample
(41.3%) had injected drugs for more than 8 years; more
than half (55.5%) used opiates regularly in the past year;
and 74.6% used multiple drugs. Almost two-thirds
(62.9%) reported sharing injection equipment in the past
year while 8.0% knew they shared with an HIV+ person.
Almost one-fourth (23.9%) back- or front-loaded a
syringe one or more times per month in the past year.
Almost half (44.8%) had received some form of treatment
for drug addiction in their lifetime. More than half (53%)
have ever used needle exchange programs. Participants
also reported in qualitative interviews that operation of
needle exchange programs was irregular, and many sites
were undermined by police intercepting or approaching
clients.
For the continuous risk variables (see Table 3), the average
HIV-KQ-45 (HIV knowledge) score was 25.9 (SD = 7.6),
which represents 57.6% of the items answered correctly
(range 0 to100% correct) [17]. Average RAB drug risk
score was 7.5 (SD = 4.4), falling in the high risk category
(Norms: range 0–30, mean 5.04, SD 6.17, median 3).
Average RAB sex risk score was 5.1 (SD = 2.0), also in the
high risk category (Norms: range 0–27, mean 4.22, SD
3.5, median 4) [19]. The mean days of marijuana use in
the past month (30 days) was 6.0 days (SD = 8.6).
HIV and HCV related risk factors
In univariate analyses, demographic, sex and drug-use risk
variables were compared by HIV and HCV test results
(Tables 2 and 3). Among demographic variables, only
older age (>25 years) was associated with HCV seroposi-
tivity. Among the sex risk variables, past-year exchange of
sex and drugs was negatively associated with HCV serop-
ositivity. Among drug use risk variables, years of using
opiate drugs (> 8 years) increased the risk of HCV. Recent
and regular use of opiates doubled the risk of both HIV
and HCV. Sharing needles or injection equipment and
sharing with a known HIV positive person in the past year
increased the risk of HIV 1.9 and 2.6 times, respectively.
More frequent back- or front-loading of syringes and ever
receiving drug addiction treatment increased the risk of
HCV seropositivity by two-fold. Table 3 displays the uni-
variate analyses of continuous variables associated with
HIV and HCV infection. Greater HIV knowledge was asso-
ciated with HIV seropositivity, and higher (worse) RAB
drug risk scores and fewer days of marijuana use were
associated with HCV seropositivity.
In multivariate analyses (Table 4), three variables were
entered into the final model of predicting HIV infection,
and all were retained. HIV seropositivity was positively
associated with HIV knowledge (adjusted odds ratio
(AOR), 1.1; 95% CI, 1.04, 1.15). Using opiate drugs daily
or almost daily in the past year was associated with more
than a two-fold increase in HIV risk (AOR, 2.2; 95% CI,
1.05–4.46). Those who had shared needles/syringes with
an HIV positive person in the past year had more than
three times the HIV risk of those who had not shared
(AOR, 3.4; 95% CI, 1.24, 9.3). Seven variables were
entered into the final model to predict HCV infection, and
three were retained. Those who back- or front-loaded at
least once per month in the past year had four times the
HCV risk of those engaged in this practice less than one
time per month (AOR, 4.0; 95% CI, 1.5–11.90). A one-
day increase of marijuana use in the past month was asso-
ciated with a 4% decrease of HCV risk (AOR, 0.96; 95%
CI, 0.93–0.99). Those who had ever been treated for drug
addiction or used a needle exchange had 2.4 times the risk
of HCV compared to those who had never accessed these
services (AOR, 2.4; 95% CI, 1.3–4.5).
Discussion
This study revealed that, in a community sample of injec-
tion drug users in central Ukraine (Vinnitsya Oblast), HIV
and HCV prevalence are 14% and 73%, respectively, with
co-infection among 12% of the IDU population sampled.
These data provide evidence that HIV and HCV infections
are prevalent among injection drug users of mostly hanka
or home-made opiates in agricultural-based central
Ukraine. The findings add to Booth's HIV prevalence find-
ings of 34% in Kiev (major metropolitan area), 51% in
Odessa (southern seaport), and 17% in Makeevka/
Donesk (eastern mining region) in Ukraine [11]. They
support the conclusion that multiple blood-borne infec-
tions among IDUs have reached epidemic proportions
across Ukraine [20].
Central Ukraine seems to be experiencing one of the lower
regional IDU HIV prevalence rates in this country. Differ-
ences in HIV prevalence by region may be explained by
Table 1: Prevalence of HIV and hepatitis C virus (HCV) 
infections among injection drug users in Vinnitsya, Ukraine.
HIV status # (%) HCV status # (%)
Positive Negative Total
Positive 38 (12.1%) 6 (1.9%) 44 (14.0%)
Negative 192 (61.0%) 79 (25.1%) 271 (86.0%)
Total 230 (73.0%) 85 (27.0%) 315 (100.0%)Harm Reduction Journal 2009, 6:23 http://www.harmreductionjournal.com/content/6/1/23
Page 5 of 9
(page number not for citation purposes)
Table 2: Univariate analysis of categorical factors associated with HIV and hepatitis C virus (HCV) infections among injection drug 
users in Vinnitsya, Ukraine (Unadjusted odds ratios with 95% confidence interval).
Factors No. of participants No. of HIV positives 
(row %)
Unadjusted odds ratio 
(95% C.I.)
No. of HCV positives 
(row %)
Unadjusted odds ratio 
(95% C.I.)
Sex
Female 57 8 (14.1) 1.0 41 (71.9) 1.0
Male 258 36 (14.0) 0.99 (0.5, 2.4) 189 (73.3) 1.01 (0.6, 2.0)
Age
≤ 25 years 120 14 (11.7) 1.0 79 (65.8) 1.0
>25 years 195 30 (15.4) 1.4 (0.7, 2.8) 151 (77.4) 1.8 (1.1, 3.0) **
Education§
High school or less 191 27 (14.1) 1.0 141 (73.8) 1.0
Some college or above 119 16 (13.5) 0.9 (0.5, 1.8) 85 (71.4) 0.9 (0.5, 1.5)
Currently unemployed
No 99 16 (16.2) 1.0 72 (72.3) 1.0
Yes 216 28 (13.0) 0.8 (0.4, 1.5) 158 (73.2) 1.0 (0.6, 1.7)
Number of sexual partners in the past year
≤1 154 23 (14.9) 1.0 114 (74.0) 1.0
>1 161 21 (13.0) 0.8 (0.4, 1.6) 116 (72.1) 0.9 (0.5, 1.5)
Exchanging sex for drugs or drugs for sex in the past year§
No 278 40 (14.4) 1.0 207 (74.5) 1.0
Yes 33 3 (9.1) 0.6 (0.1, 1.8) 19 (57.6) 0.5 (0.2, 1.0) **
No use or inconsistent use of condoms
No 145 22 (15.2) 1.0 106 (73.1) 1.0
Yes 165 21 (12.7) 0.8 (0.4, 1.6) 120 (72.7) 1.0 (0.6, 1.6)
Years of using opiate drugs
≤ 8 years 185 27 (14.6) 1.0 124 (67.0) 1.0
>8 years 130 17 (13.1) 0.9 (0.5, 1.7) 106 (81.5) 2.2 (1.3, 3.8) ***
Using opiate drugs daily or almost daily in the past year
No 137 12 (8.8) 1.0 90 (65.7) 1.0
Yes 171 32 (18.7) 2.4 (1.2, 4.9)* 137 (80.1) 2.1 (1.3, 3.5) ***
Using multiple drugs in the past year
No 80 11 (13.8) 1.0 58 (72.5) 1.0
Yes 235 33 (14.0) 1.0 (0.5, 2.2) 172 (73.2) 1.0 (0.6, 1.8)
Sharing needles or injection equipment in the past year§
No 116 11 (9.5) 1.0 80 (69.0) 1.0
Yes 197 32 (16.2) 1.9 (0.9, 4.0) * 148 (75.1) 1.4 (0.8, 2.3)
Sharing needles with an HIV-positive person in the past year§
No 286 37 (12.9) 1.0 210 (73.4) 1.0Harm Reduction Journal 2009, 6:23 http://www.harmreductionjournal.com/content/6/1/23
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the history of the HIV epidemic. HIV was initially intro-
duced in Kiev and southern seaport cities; spread from
there to the east; and only later began to affect other
regions [5,14]. By the time that larger scale testing and
prevention programs were rolled out, the epidemic in
Kiev and the south was in an advanced phase. Other
regions were in an earlier (and thus lower prevalence)
stage when voluntary counseling and testing and harm
reduction programs became available. There are no
reported differences in injection practices across different
regions of Ukraine, although it is possible that more
home-made hanka is used in Central Ukraine whereas
more imported prepared heroin is available in larger cities
and seaports. This, however, would seem to lead to greater
HIV transmission among home-made hanka users due to
more prevalent sharing practices. On the other hand,
dependence on seasonal use (when the poppy plants can
be harvested) may be associated with less use and ulti-
mately less risk. The hypothesis that variations in either
chemistry or in patterns of administration by IDUs may
have a substantial role in shaping the epidemic was sub-
stantiated by Ciccarone and Bourgois among IDUs in the
United States. They found that specific patterns of use
(extra heating and cleaning of needles) of Mexican-
derived heroin, commonly referred to as "black tar" her-
oin, may have retarded the spread of HIV in some U.S.
states where black tar heroin predominates [21]. Further
primary and secondary data sources and ethnographic
research are needed to relate cultural IDU practices to HIV
and HCV prevalence in Ukraine.
The cultural preparation, distribution and sharing prac-
tices of Central Ukraine are prime targets for prevention
through education and, more importantly, through insti-
tuting accessible, stably operating needle exchange pro-
grams that can establish a first link between the IDU and
Yes 25 7 (28.0) 2.6(1.0, 6.5) ** 17 (68.0) 0.8 (0.3, 1.9)
Frequency of back- or front-loading in the past year§
Less than 1 time per 
month
236 33 (14.0) 1.0 162 (68.6) 1.0
One or more times 
per month
74 10 (13.5) 0.96 (0.5, 2.1) 63 (85.1) 2.6 (1.3, 5.3) **
Ever received drug addiction treatment?§
No 171 19 (11.1) 1.0 110 (64.3) 1.0
Yes 139 24 (17.8) 1.7 (0.9, 3.2) 116 (83.5) 2.8 (1.6, 4.8)
***
Note.§ There are missing data due to no response; * P < 0.1; ** P < 0.05; *** P < 0.01.
Table 2: Univariate analysis of categorical factors associated with HIV and hepatitis C virus (HCV) infections among injection drug 
users in Vinnitsya, Ukraine (Unadjusted odds ratios with 95% confidence interval). (Continued)
Table 3: Univariate analysis of continuous factors associated with HIV and hepatitis C virus (HCV) infections among injection drug 
users in Vinnitsya, Ukraine (Mean ± SD; p-value for significance of mean differences using Student's t-test).
Total HIV- HIV+ p-value HCV- HCV+ p-value
HIV-KQ-45 score, points
25.9 ± 7.6 25.3 ± 7.7 29.5 ± 6.4 0.0003 24.6 ± 7.7 26.4 ± 7.6 ns
RAB drug risk score, points
7.5 ± 4.4 7.5 ± 4.3 8.0 ± 5.0 Ns 6.7 ± 4.3 7.8 ± 4.5 0.04
RAB sex risk score, points
5.1 ± 2.0 5.1 ± 2.0 5.2 ± 2.3 Ns 5.2 ± 2.0 5.1 ± 2.0 ns
Days of marijuana use in the past month
6.0 ± 8.6 6.0 ± 8.6 5.9 ± 8.7 Ns 8.0 ± 10.7 5.3 ± 7.6 0.04Harm Reduction Journal 2009, 6:23 http://www.harmreductionjournal.com/content/6/1/23
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the health care community. Furthermore, by attracting
IDUs through street outreach and providing them with a
source of clean needles and syringes, we then can advocate
effectively for harm reduction, risk reduction, and HIV
testing and provide prevention education and addiction
treatment as demonstrated in other Ukrainian cities [8].
Our study confirms that the coverage of effective preven-
tion programs such as needle exchange remains insuffi-
cient in the central region of Ukraine and should be scaled
up to lower HIV incidence.
The phenomenon that HCV is more common than HIV
among IDUs is well documented [22-25]. HIV and HCV
share the major risk factor of percutaneous exposure, and
small-volume percutaneous exposure is more effective for
HCV transmission than for HIV transmission [26-28].
However, this study offers no clear scientific explanations
as to why HCV is higher than HIV in these groups of injec-
tors, given the findings that each infection was associated
with unique but equally risky transmission injection prac-
tices: sharing needles with HIV-positive drug users (HIV+
group) and back- and front-loading (HCV+ group). Mari-
juana use was identified as a protective factor for HIV
infection. Marijuana use may be associated with off-sea-
son periods when home-made hanka is harder and more
expensive to get. Use of marijuana to relieve withdrawal
symptoms and, ultimately, lack of hanka access may be
associated with lower HIV risk (less frequent or more spo-
radic injection use).
Whereas HIV has been the focus of attention in harm
reduction programs among IDUs in Ukraine and other
European countries, HCV has been largely ignored and
treatment perceived as too expensive. Our study findings
underscore the importance of including diagnosis and
basic care for HCV co-infection in HIV prevention and
treatment programs. Antiretroviral therapy for HIV and
interferon/ribavirin schemes for HCV have proven effec-
tive in reducing mortality and increasing quality of life
[29-31]. These treatments are becoming more available in
Ukraine, thus making early diagnosis vitally important for
those infected. We found that 12% of study participants
were co-infected with HIV and HCV. HCV may facilitate
HIV disease progression and increase the incidence of
liver toxicity associated with certain antiretroviral regi-
mens. HCV co-infection represents a leading cause of
morbidity and mortality among AIDS patients receiving
antiretroviral therapy (ART) [32,33].
Limitations
We used rapid screening tests for detecting HIV and HCV
antibodies. We did not perform HCV RNA tests or recom-
binant immunoblot tests; therefore, false negative cases
may exist in patients with severe cellular immune suppres-
sion as a result of HIV [34]. This may result in underesti-
mation of HCV prevalence. HIV antibody screening may
produce false positive results and lead to overestimation
of HIV prevalence. However, the benefits of using rapid
tests are increased participation and receipt of testing
results and post-test counseling. The sample consists of
volunteers recruited by a snowball sampling technique,
beginning with seven "seeds." The strategy was quite effec-
tive in recruiting eligible IDUs from the home-made opi-
ate injecting community, and a substantial proportion of
the total estimated IDU population (380 out of estimated
2300 or 16.5%) participated. The sample does represent
the networks of users initiated from the original 7 partici-
pants. But despite the fact that all initial participants were
recruited from a narcological treatment facility, and there-
fore were included in the official registry of drug depend-
Table 4: Multivariate logistic regression analysis of factors associated with HIV and hepatitis C virus (HCV) infections infection among 
injection drug users in Vinnitsya, Ukraine.
Variable Model unit Adjusted odds ratio 95% confidence interval p-value
Model: HIV (N = 268)
HIV knowledge (HIV-KQ-45) score 1 score point 1.1 1.04, 1.15 <0.001
Using opiate drugs daily or almost daily in the past year Yes/no 2.2 1.05, 4.46 0.04
Sharing needles/syringes with HIV positive person in the past year Yes/no 3.4 1.24, 9.3 0.02
Model: HCV (N = 274)
Frequency of back- or frontloading in the past year ≥1 vs. <1 per month 4.0 1.5, 11.0 <0.01
Days of marijuana use in the past month 1 day of use 0.96 0.93, 0.99 0.02
Ever used drug addiction treatment Yes/no 2.4 1.3, 4.5 <0.01
Note. Complete participant records from (N = 315) were excluded from the models if any variable was missing.Harm Reduction Journal 2009, 6:23 http://www.harmreductionjournal.com/content/6/1/23
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ent persons at RND, our sample went beyond the
treatment-exposed cluster of IDUs and included 55% who
were not registered with the government treatment sys-
tem. It appears that most participants were experienced
users, as evidenced by high prevalence of physical stig-
mata of injection. Future studies should assure representa-
tion of new or careful injectors as well. Results of prior
HCV and HIV testing were not used to exclude volunteers,
which makes it difficult to identify true undiagnosed
cases. Finally, there were no data collected indicating
whether needle sharing preceded or followed HIV infec-
tion. To better differentiate HIV transmission versus
acquisition risk behaviors, future research should strive to
specify the circumstances surrounding HIV status, knowl-
edge of status, and sharing behaviors.
Conclusion
HIV and HCV are common among IDUs in central
Ukraine. Efforts should be increased to implement educa-
tion and harm reduction strategies to decrease unsanitary
preparation and risky distribution and injection practices
related to home-made opiate use in Central Ukraine. Gov-
ernmental and non-governmental treatment of opiate
IDU and HIV should also include testing and treatment of
HCV. Harm reduction programs should be scaled up to
reduce risks of HIV and HCV infection among IDUs and
to prevent transmission to the general population
through heterosexual contact.
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